Indivior Pharmaceuticals, Inc 6-K, filed Feb 29, 2024
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2024-02-29
For: 2024-02-29
View Original
Added on
July 07, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on February 29, 2024.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: February 29, 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit
No.
|
Description of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: February 29,
2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
Court Provides Final Approval of Settlement with Direct Purchaser
Class in the Multidistrict Antitrust Litigation; Final Court
Approval Concludes the Antitrust Multidistrict
Litigation
Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq:
INDV), a leading addiction
treatment company, today announced that its subsidiary, Indivior
Inc., has received final Court approval for its settlement with the
Direct Purchaser class, concluding the anti-trust multi-district
litigation ("MDL") matter.
On October 22, 2023, Indivior Inc. entered into a settlement
agreement with the remaining Direct Purchaser class for $385m. On
February 27, 2024, the United States District Court for the Eastern
District of Pennsylvania entered an order granting final judgement
and order of dismissal approving the Direct Purchaser class
settlement and dismissing the Direct Purchaser class claims. This
ruling concludes the Antitrust MDL.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat addiction and
serious mental illnesses. Our vision is that all patients around
the world will have access to evidence-based treatment for the
chronic conditions and co-occurring disorders of substance use
disorder (SUD). Indivior is dedicated to transforming SUD from a
global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a
pipeline of product candidates designed to both expand on its
heritage in this category and potentially address other chronic
conditions and co-occurring disorders of SUD, including alcohol use
disorder and cannabis use disorder. Headquartered in the
United States in Richmond, VA, Indivior employs more
than 1,100 individuals globally and its portfolio of products is
available in 37 countries worldwide.
Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Media
Contacts:
US Media:
Cassie France-Kelly
Vice President, Communications
Indivior PLC
Tel: 804-724-0327
UK Media:
Teneo
Tel: +44 207-353-4200
Investors
and Analysts:
Jason Thompson
Vice President, Investor Relations
Indivior PLC
Tel: 804-402-7123
Tim Owens
Director, Investor Relations
Indivior PLC
Tel: 804-263-3978
-ends-